INCA33890
Sponsors
Incyte Corp., Incyte Corporation, Groupe Oncologie Radiotherapie Tete et Cou
Conditions
Advanced Solid TumorsCRC (Colorectal Cancer)Head and Neck Cancer Squamous Cell CarcinomaMetastatic Microsatellite Stable Colorectal CancerMetastatic Solid TumorsSolid Tumors
Phase 1
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
RecruitingNCT05836324
Start: 2023-07-24End: 2029-05-03Target: 570Updated: 2026-07-23
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
RecruitingNCT06179160
Start: 2024-01-04End: 2027-01-01Target: 710Updated: 2026-07-22
Phase 2
A Study to Evaluate INCA33890 in the Treatment of Circulating Tumor DNA-Positive Stage II/III Microsatellite Stable Colorectal Cancer After Curative Resection and Chemotherapy
Not yet recruitingNCT07823322
Start: 2026-10-26End: 2029-05-14Target: 40Updated: 2026-09-22
A Clinical Trial Comparing an Antibody (INCA33890) Versus Pembrolizumab for Squamous Cell Carcinoma of the Head and Neck.
Not yet recruitingNCT07876414
Start: 2027-02-01End: 2030-12-01Target: 78Updated: 2026-10-22
Phase 3
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
RecruitingNCT07284849
Start: 2026-03-05End: 2029-09-28Target: 700Updated: 2026-10-09
A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
Not yet recruitingCTIS2025-523735-19-00
Target: 106Updated: 2026-05-20